Blue Bell, PA – According to filings with the U.S. Securities and Exchange Commission, Seneca Therapeutics is raising $3,250,000.00 in new funding. Sources indicate as part of senior management President, Paul Hallenbeck played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Seneca Therapeutics

Seneca Therapeutics is a privately held, clinical-stage cutting edge biotechnology company focused on developing novel oncolytic immunotherapeutics for the treatment of cancer. Seneca’s lead asset is SVV, an oncolytic virus of the genus Seneca in the picornavirus family that is characterized by its ability to replicate selectively in certain human tumor cells (SVV-permissive cells).

To learn more about Seneca Therapeutics, visit http://senecatherapeutics.com/

Contact:
Paul Hallenbeck, President
484-883-9725
https://www.linkedin.com/in/paulhallenbeck/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved